CA
NZ
UK
AU
IND
US
• Definium Therapeutics (NASDAQ: DFTX) plans to sell $500 million in common shares and pre‑funded warrants in a public offering.
• HeartBeam (NASDAQ: BEAT) restructures leadership, transitioning to a model led by founder Branislav Vajdic and Executive Chairman Rich Ferrari.
• The incoming director brings extensive experience in healthcare leadership and corporate governance.
• MoonLake Immunotherapeutics (NASDAQ: MLTX) has initiated a $200 million equity and warrant sale to bolster its financial resources.
• PAVmed Inc. (NASDAQ: PAVM) filed an 8-K with the SEC detailing amendments to its employee stock purchase plan (ESPP).
• SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) updates executive severance terms, including a one-half (1.5) times payment for the year in which employment terminates.
• Carolyn Starrett joins Neogenomics Inc (NASDAQ: NEO) Board of Directors with over two decades of experience in healthcare leadership and commercial strategy.
• Underwriters received a 30‑day option to buy up to 741,758 additional shares.
• Upexi Inc (NASDAQ: UPXI) has entered into a securities purchase agreement to reduce existing debt by approximately $19.5 million.
• The postponement gives shareholders extra time to consider key governance proposals.
Please wait processing your request...